Effects of treatment with zofenopril in men and women with acute myocardial infarction: Gender analysis of the SMILE program

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Franconi, Flavia ^a   Omboni, Stefano ^b   Ambrosioni, Ettore ^c   Reggiardo, Giorgio ^d   Campesi, Ilaria ^a   Borghi, Claudio ^c  

^a UNIVERSITY OF SASSARI   (Italy)

^b ITALIAN INSTITUTE OF TELEMEDICINE   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d Mediservice   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LISINOPRIL; PLACEBO; RAMIPRIL; ZOFENOPRIL; ANTIHYPERTENSIVE AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACUTE HEART INFARCTION; ANGIONEUROTIC EDEMA; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COUGHING; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HOSPITALIZATION; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SEX DIFFERENCE; SOUTHERN EUROPE; SURVIVAL RATE; SURVIVAL TIME; AGED; ANALOGS AND DERIVATIVES; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CAPTOPRIL; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; TREATMENT OUTCOME;

EID: 84909587219     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111558     Document Type: Article

References (39)

1. Franconi F, Carru C, Spoletini I, Malorni W, Vella S, et al. (2011) A GENSbased approach to cardiovascular pharmacology: impact on metabolism, pharmacokinetics and pharmacodynamics. Ther Deliv 2:1437-1453.
2. Franconi F, Carru C, Malorni W, Vella S, Mercuro G (2011) The effect of sex/gender on cardiovascular pharmacology. Curr Pharm Des 17:1095-1107.
3. Maas AH, Van Der Schouw YT, Regitz-Zagrosek V, Swahn E, Appelman YE, et al. (2011) Red alert for women's heart: the urgent need for more research and knowledge on cardiovascular disease in women: proceedings of the workshop held in Brussels on gender differences in cardiovascular disease, 29 September 2010. Eur Heart J 32:1362-1368.
4. West of Scotland Coronary Prevention Study (1996) Identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 348:1339-1342.
5. Raz L, Miller VM (2012) Considerations of sex and gender differences in preclinical and clinical trials. Handb Exp Pharmacol 214:127-147.
6. Franconi F, Campesi I (2014) Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women. Br J Pharmacol 171:580-594.
7. Hilliard LM, Sampson AK, Brown RD, Denton KM (2013) The "his and hers" of the renin-angiotensin system. Curr Hypertens Rep 15:71-79.
8. Komukai K, Mochizuki S, Yoshimura M (2010) Gender and the reninangiotensinaldosterone system. Fundam Clin Pharmacol 24:687-698.
9. Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, et al. (2003) Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 41:1529-1538.
10. Seeland U, Regitz-Zagrosek V (2012) Sex and gender differences in cardiovascular drug therapy. Handb Exp Pharmacol 214:211-236.
11. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, et al; Second Australian National Blood Pressure Study Group (2003) A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348:583-592.
12. Mackay FJ, Pearce GL, Mann RD (1999) Cough and angiotensin II receptor antagonists: cause or confounding? Br J Clin Pharmacol 47:111-114.
13. Slater EE, Merrill DD, Guess HA, Roylance PJ, Cooper WD, et al. (1988) Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA 260:967-970.
14. Woodard-Grice AV, Lucisano AC, Byrd JB, Stone ER, Simmons WH, et al. (2010) Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet Genomics 20:532-536.
15. Shah MR, Granger CB, Bart BA, McMurray JJ, Petrie MC, et al. (2000) Sexrelated differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry. Am J Med 109:489-492.
16. Von Lueder TG, Krum H (2013) RAAS inhibitors and cardiovascular protection in large scale trials. Cardiovasc Drugs Ther 27:171-179.
17. Borghi C, Bacchelli S, Degli Esposti D (2012) Long-term clinical experience with zofenopril. Expert Rev Cardiovasc Ther 10:973-82.
18. Ambrosioni E (2007) Defining the role of zofenopril in the management of hypertension and ischemic heart disorders. Am J Cardiovasc Drugs 7:17-24.
19. Ambrosioni E, Borghi C, Magnani B (1995) The effect of the angiotensinconvertingenzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 332:80-85.
20. Borghi C, Ambrosioni E; Survival of Myocardial Infarction Long-term Evaluation-2 Working Party (2003) Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am Heart J 145:80-87.
21. Borghi C, Ambrosioni E; Survival of Myocardial Infarction Long-term Evaluation Study Group (2007) Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE) - ISCHEMIA study. Am Heart J 153:445.e7-14.
22. Borghi C, Ambrosioni E, Novo S, Vinereanu D, Ambrosio G; SMILE-4 Working Party (2012) Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, doubleblind, parallel-group, multicenter, European study (SMILE-4). Clin Cardiol 35:416-423.
23. Hausmann R, Tyson LD, Bekhouche Y, Zahidi S (2011) The Global Gender Gap Report 2011.
24. Debray TP, Moons KG, Abo-Zaid GM, Koffijberg H, Riley RD (2013) Individual participant data meta-analysis for a binary outcome: one-stage or two-stage? PloS One 8:e60650.
25. Caldwell DM, Ades AE, Higgins JP (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331:897-900.
26. Numbeo at www.numbeo.com.
27. Papakonstantinou NA, Stamou MI, Baikoussis NG, Goudevenos J, Apostolakis E (2013) Sex differentiation with regard to coronary artery disease. J Cardiol 62:4-11.
28. Solimene MC (2010) Coronary heart disease in women: a challenge for the 21st century. Clinics (Sao Paulo) 65:99-106.
29. Montaye M, Bingham A, Arveiler D, Ruidavets JB, Ducimetière P, et al. (2013) Interregional differences in the clinical, biological and electrical characteristics of first acute coronary events in France: results from the MONICA registries. Eur J Prev Cardiol 20:275-282.
30. Law MR, Morris JK (1998) Why is mortality higher in poorer areas and in more northern areas of England and Wales? J Epidemiol Community Health 52:344-352.
31. Menotti A, Mulder I, Nissinen A, Giampaoli S, Feskens E J M, et al. (2001) Prevalence of morbidity and multimorbidity in elderly male populations and their impact on 10-year all-cause mortality: The Fine study (Finland, Italy, Netherlands, Elderly). J Clin Epidemiol 54:880-886.
32. Ducimetière P, Ruidavets JB, Montaye M, Haas B, Yarnell J, on behalf of the Prime Study group (2001) Five-year incidence of angina pectoris and other forms of coronary heart disease in healthy men aged 50-59 in France and Northern Ireland: the Prospective Epidemiological Study of myocardial infarction (PRIME) study. Int J Epidemiol 30:1057-1062.
33. Morris RW, Whincup PH, Emberson JR, Lampe FC, Walker M, et al. (2003) North-south gradients in Britain for stroke and CHD: are they explained by the same factors? Stroke 34:2604-2609.
34. Puymirat E, Battler A, Birkhead J, Bueno H, Clemmensen P, et al., on behalf of the EHS 2009 snapshot participants (2013) Euro Heart Survey 2009 Snapshot: regional variations in presentation and management of patients with AMI in 47 countries. Eur Heart J Acute Cardiovasc Care 2:359-370.
35. Mirzaei M, Truswell AS, Taylor R, Leeder SR (2009) Coronary heart disease epidemics: not all the same. Heart 95:740-746.
36. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, et al.; European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG) (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 33:1635-1701.
37. Schmotzer GL (2012) Barriers and facilitators to participation of minorities in clinical trials. Ethn Dis 22:226-230.
38. Dodd KS, Saczynski JS, Zhao Y, Goldberg RJ, Gurwitz JH (2011) Exclusion of older adults and women from recent trials of acute coronary syndromes. J Am Geriatr Soc 59:506-511.
39. Omboni S, Borghi C (2011) Zofenopril and incidence of cough: a review of published and unpublished data. Ther Clin Risk Manag 7:459-471.